DNATIX.COM Due Diligence
The primary goal is to perform due diligence on the founders of dnatix.com. Is there anything important or noteworthy about them, especially when it concerns making an investment in the company.
- The company has three co-founders: Ofer A. Lidsky, Tal Sines, Ichak Adizes.
- Sines and Lidsky have been friends since 1985.
- The aim of this company is to flip the genetic industry on it's head.
- In 2018, DNAtix showed that they can compress the DNA sequence up to 99% of its original size.
- The company was listed in The Silicon Review for 2018 as one of the 50 most trustworthy companies.
- There haven't been any noticable complaints about or against the company as of 08/13/19.
- The company's Facebook page is here: however, other social media accounts for the founders aside from LinkedIn were not found.
Ofer A. Lidsky
- On the DNAtix website Lidsky is described as an expert in cybersecurity and cloud storage as well as an experienced entrepreneur in "Software Development, Cybersecurity, and Digital Health."
- The following is Lidsky's LinkedIn profile.
- He is the founder and CEO of TerraSafe Ltd and has been working in the computer industry for 30 years.
- Lidsky is also the CEO of Excellent Brain. He has one published resource on Research Gate.
- This video interview shows Lidsky's personality and thought process.
- Sines is a molecular biology expert and a patent attorney. He has "worked as IP Director at T3 at the Technion Research and Development Foundation and at Hadassah Ein Kerem and Hadassah Mount Scopus Hospitals."
- His LinkedIn profile can be found here.
- Crunchbase reports that DNAtrix is the only company Sines has founded.
- Sines has published five medical research papers/reports.
Competitors to DNATIX
- Luna DNA
- Orion Health
- Nebula Genomics
Proposed next steps:
You need to be the project owner to select a next step.
Initial research reveals that there is little additional information to be gained about Ofer A. Lidsky and Tal Sines personal life, whereas Ichak Adizes is more open in what he shares. There is very little to no negative press about any of the co-founders nor the company.
In order to make a sound investment, having a basic overview of the eight competitors outlined above may be beneficial. An overview can be provided in groups of four companies each explaining what recent press surrounds the company, their current revenues, and what their value add to the genetics industry is.